Articles tagged with Cancer Patients
A study published in Circulation found that patients with acute thrombosis in the leg are at a three-fold higher risk of developing cancer during the first six months after the blood clot. The risk is highest for smoking-related forms of cancer, such as lung and pancreatic cancer.
Scientists developed a high-speed microscopy platform that can measure tumor sensitivity to drugs in hours, rather than days, and has shown promising results in treating melanoma
Researchers from SU2C and Cancer Research Institute found that administering immunotherapy before surgery activates T-cells to hunt and destroy distant cancerous cells, preventing relapse. The approach showed encouraging outcomes in 45% of patients, with few evidence of cancer remaining upon follow-up.
A preclinical study by MD Anderson Cancer Center researchers found that precancerous colon polyps in patients with Lynch syndrome display immune system activation, challenging traditional models of cancer immune activation. The study suggests immunotherapy may be useful for colorectal cancer prevention in certain high-risk groups.
The SU2C Multiple Myeloma Dream Team aims to revolutionize the treatment of the incurable blood cancer by detecting precursor conditions such as MGUS or SMM. The team plans to analyze blood samples from approximately 50,000 people to identify biomarkers that can predict high-risk progression.
Researchers found that giving patients a single dose of anti-PD-1 therapy before surgery can predict tumor response and patient outcomes. The study also revealed that immune cells active against cancer were present in patients with longer recurrence-free survival.
A phase I clinical trial of BLU-667, a novel precision-targeted drug, reports significant durable disease control in patients with RET-driven cancers. The study reveals an overall response rate of 37% for RET-driven cancers, with responses of 45% for non-small cell lung cancer.
A study found that patients with a treating pivot nurse had higher patient satisfaction scores and better quality-of-life outcomes compared to those without such support. The coordinated care improved patients' understanding of their disease, treatment side-effects, and overall strength in fighting cancer.
A new study reports that consuming high amounts of carbohydrates and sugar prior to treatment for head and neck cancer may increase patients' risks of cancer recurrence and mortality. However, moderate fat and starchy food consumption after treatment appears to have protective benefits, reducing disease recurrence and death rates.
A lifestyle consistent with American Cancer Society (ACS) guidelines was associated with a lower risk of death in patients with stage III colon cancer. Patients who followed these guidelines had improved survival rates compared to those who did not.
Researchers found that simultaneous chemotherapy and immunotherapy is safe and patients with certain genetic mutations may respond particularly well. The combination approach was shown to boost immune cells in the blood, allaying previous concerns about chemotherapy's impact on immunotherapy.
A new NCI study revises molecular classification for diffuse large B-cell lymphoma, identifying four prominent genetic subtypes that can help explain treatment response. The study's findings will aid in predicting prognosis and tailoring therapy for patients with DLBCL.
Research analysis found unintended weight loss to be the second-highest risk factor for some forms of cancer. The study of 11.5 million patients revealed significant associations with colorectal, lung, pancreatic, and renal cancers, emphasizing the need for streamlined services to investigate non-specific symptoms like weight loss.
A study found that only 16% of respondents were aware of drug shortages, and those with a personal history of cancer were more likely to be aware. Most respondents wanted to be informed about substitution due to shortages and would transfer care to avoid major differences in efficacy.
A large study of breast cancer patients found that radiotherapy and chemotherapy do not significantly increase the risk of heart disease. Good risk management in hospitals and short interval screenings may offset elevated risks. The study's findings are considered positive for treatment of breast cancer.
A groundbreaking cancer genomics study reveals new molecular classifications, enabling the re-classification of 33 tumor types into 28 distinct clusters. These findings hold promise for immune-based and other novel cancer therapeutics, as well as repurposing drugs used to treat other diseases.
The PDX Finder is a free global portal for cancer models, offering over 1900 clinically relevant models from multiple repositories. Researchers can search and submit their own models to accelerate collaborative research and time-saving.
Researchers analyzed genomic and molecular data from 33 cancer types and identified 28 molecular clusters. The study provides new insights into cancer classification and potential treatment options.
Researchers have developed a new classification system for cancer based on molecular characteristics, identifying 28 subtypes and improving treatment options. The new approach has the potential to revolutionize cancer diagnosis and patient care.
Researchers created patient-specific bladder cancer organoids that mimic actual tumors, allowing for testing of multiple drugs and predicting individual response to treatment. The use of these personalized models may improve understanding of the genomics of bladder cancer and develop new therapies.
Scientists at the Medical University of South Carolina discovered a specific form of transforming growth factor-beta (TGF-beta) that binds to glycoprotein-A repetitions predominant (GARP), regulating B cell activity. The GARP:TGF-beta axis may serve as a diagnostic marker and therapeutic target for autoimmune diseases.
The NIH has completed a comprehensive genomic analysis of 33 cancer types, revealing new insights into tumor origins, progression, and vulnerabilities. The PanCancer Atlas provides a detailed understanding of how tumors arise in humans, enabling better informed clinical trials and future treatments.
A new approach to treating malignant pleural effusion in cancer patients combines talc with an indwelling pleural catheter, allowing for effective home-based treatment. The study found that patients treated with this combination were more than twice as likely to have their fluid dry up compared to those treated with IPC alone.
The American Cancer Society has approved funding for 110 grants totaling $47,624,000 to researchers at 72 institutions. Grants focus on improving treatments for various types of cancer, including lymphoma, breast cancer, and sarcomas.
Researchers have discovered a new function of the APC protein, which puts the brakes on colon cancer activators. This finding may lead to identification of additional drug targets and improved therapeutic strategies for colon cancer patients.
Researchers found that gut microbiome manipulation can significantly boost efficacy of adoptive T cell therapy in mice with cancer. Fecal transplants and antibiotic use increased anti-tumor response and remission rates, highlighting a crucial role for the gut microbiota in cancer treatment.
Researchers found a single upfront genomic test to be more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than traditional multiple testing. This approach helps guide treatment decisions while identifying those at risk of developing CRC and other cancers.
Larotrectinib, a new pediatric cancer drug targeting the TRK gene fusion, showed an unprecedented 93 percent response rate in patients tested. The drug has been effective in treating rare pediatric cancers such as infantile fibrosarcoma and papillary thyroid cancer.
Patients with alcohol-related liver cancer tend to have poorer overall survival rates compared to those with non-alcohol related liver cancer. The study highlights the need for improved screening and treatment programs for patients at risk of developing cirrhosis or liver cancer, especially those who are still drinking.
A global clinical trial collaboration published in the New England Journal of Medicine found that stage III colon cancer patients can cut their chemotherapy treatments in half after surgery, reducing costs and side effects. For low-risk patients with shallow tumors and few affected lymph nodes, a three-month course is shown to be safe ...
The SU2C Phillip A. Sharp Innovation in Collaboration Awards aim to strengthen collaboration among scientists conducting cancer research, with five teams receiving $1.25 million to work on new projects across institutional and national lines. The grants focus on synergies among researchers from different institutions and skill sets.
The BIABooster device characterizes DNA in blood circulation with new precision and sensitivity, identifying promising signatures for cancer monitoring. It has been shown to detect DNA up to a concentration of 10 fg/μL with precisions of 20% and 3%.
A pen and paper chart, EPAT, helps doctors regularly record pain levels using a traffic light system, leading to reduced pain in cancer patients, and improved monitoring of medications and side effects. The study suggests this simple approach can put pain management at the forefront of routine care, with potential benefits for patients.
A Singapore-led team of Asian cancer researchers has won the prestigious AACR Team Science Award for their groundbreaking work on cancers prevalent in Asia. The team's research has identified new genes and pathways, translated findings into clinical trials, and informed government policies.
Researchers analyzed 5,298 patients with surgically removed ampullary tumors and found no survival benefit from adjuvant therapy. Patients receiving additional chemotherapy or radiation therapy did not show improved stage-specific survival rates compared to those who underwent surgery alone.
A recent NRG Oncology study found that high-dose radiotherapy improves biochemical control and reduces distant metastases in men with intermediate-risk prostate cancer, but does not enhance overall survival. The treatment also resulted in more side effects compared to standard radiotherapy.
A newly designed chimera could simultaneously decrease the expression of three growth factors that are over-expressed in some cancers, leading to cancer cell death. The molecule has potent anti-tumor activity and is non-toxic, simple to produce, and cost-effective compared to traditional treatment strategies.
Researchers at Johns Hopkins Medicine have developed a non-invasive test called UroSEEK, which uses urine samples to detect DNA mutations associated with bladder cancer. The test significantly enhances early detection for patients at risk and surveillance of those who have already been treated. When combined with cytology, the sensitiv...
A new model predicts the extra risk of death for breast cancer patients and survivors, taking into account improved survival rates over time. The model could lead to lower life insurance premiums and increased transparency for patients.
A study found that patients with ductal carcinoma in situ (DCIS) who are post-menopausal or estrogen receptor positive have a low risk of recurrence. Treatment with breast-conserving surgery and radiotherapy leads to very low rates of recurrence. The research also identifies clues for tailoring treatments to individual patients.
Researchers collected three tumor samples from a patient with salivary gland cancer, revealing a significant increase in cancer stem cells and aggressive mutations over time. This study demonstrates how tumors can adapt and overcome therapies, leading to relapse and treatment resistance.
A new study by NYU Langone Health reveals that patients from lower-income areas have a significantly reduced chance of surviving anal cancer. The research, led by Dr. Daniel Becker, found a strong association between median household income and overall survival rates.
Researchers established two new adrenal cancer cell lines and mouse models to test novel treatments, identifying PBK as a key target. A patient treated with pembrolizumab showed remarkable response with 77% tumor reduction, while a humanized mouse model also responded to the immunotherapy.
Researchers found that elevated methylglyoxal levels lead to insulin resistance, obesity, and high blood sugar levels in flies, challenging the conventional view of type 2 diabetes. This discovery raises questions about the molecular causes of the disease.
Patients with urological cancers, such as prostate and bladder cancer, are five times more likely to commit suicide than the general population. The study found that severe psychological stress is a major side-effect of cancer diagnosis and treatment, leading to higher rates of depression, PTSD, and suicidal intent in this patient group.
Researchers developed a new molecular classification method using DNA methylation patterns to differentiate 82 types of CNS tumors. The method improved diagnostic accuracy in some cases, with over 12% of cases corrected after analysis.
A major international survey found that around 25% of patients with penile cancer are not receiving recommended treatment. This leads to a significantly lower survival rate, with twice as many patients surviving if treated according to guidelines.
The non-profit organization Destroy Pancreatic Cancer is funding a new clinical trial designed by Dr. Daniel D. Von Hoff at the Piedmont Cancer Institute, aiming to improve treatment options for pancreatic cancer patients. The trial will enroll up to 25 patients and is part of TGen's efforts to find a cure for this deadly disease.
Research at Huntsman Cancer Institute found that estrogen and glucocorticoid receptors work together to promote more aggressive endometrial cancers. The study suggests that corticosteroids, a stress hormone, can make the uterine lining stop growing but may also contribute to tumor growth when combined with high estrogen levels.
A study published in CANCER found that living in low-income areas increases the risk of early death among patients with anal cancer. The researchers analyzed data from 9,550 patients and found that those in lower income areas had worse overall survival and cancer-specific survival compared to those in higher income areas.
A recent study found that patients are willing to travel up to 75 minutes longer and 5 hours longer to receive specialized cancer care with improved outcomes. Centralization of cancer surgery services can reduce variations in quality of care and improve patient health outcomes.
Research from the University of Pittsburgh School of Medicine discovered that preventing T-cell exhaustion with targeted therapies enhances immunotherapy outcomes. Activating a protein called 41BB on the surface of T-cells improves energy reserves and prolongs their ability to attack cancer cells.
Research reveals that breast cancer and lymphoma patients are at increased risk of developing congestive heart failure, with a threefold higher risk compared to non-cancer patients. Periodic cardiac imaging and lifestyle changes may help mitigate this risk.
Researchers from DKFZ found that circulating cancer cells exhibit specific polarity, which helps them attach to endothelial cells and migrate into tissues. This discovery may help predict individual risk for metastasis and find therapies to reduce it.
A comprehensive genomic analysis of childhood cancer reveals that children and adults have different mutated genes driving their disease, underscoring the need for pediatric-specific precision therapies. The study found that only 45% of the mutated genes 'driving' cancer in children are the same as those in adults.
Researchers found that patients with a history of breast cancer or lymphoma are three times more likely to develop heart failure than those without cancer. Elevated risks were associated with diabetes, high doses of chemotherapy, and anthracycline drugs.
A new study from St. Jude Children's Research Hospital and the American University of Beirut Medical Center demonstrates effective childhood cancer treatment in a refugee setting. The institution adapted its services to prioritize curable cases, showcasing a viable model for crisis response.
A combined analysis of family history and genetic markers improves risk prediction for colorectal cancer, revealing that individuals with a positive family history and numerous genetic variants are at increased risk. This approach can help adjust preventive measures and screening schedules.
Researchers will study basal-squamous and luminal subtypes of aggressive bladder cancer using a mouse model and human cancer cell lines. Understanding the role of TFAP2 transcription factors may lead to new therapeutic approaches for predicting patient response to treatment.
In three clinical trials, larotrectinib demonstrated a 75% overall response rate in patients with TRK fusion genes, with 86% continuing treatment or undergoing curative surgery. This study marks a new paradigm in cancer drug development, defining cancers by molecular changes rather than site of occurrence.